Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 256

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia

Open access
Lugthart, Sanne, Gröschel, Stefan, Beverloo, H. Berna, Kayser, Sabine, Valk, Peter J.M., van Zelderen-Bhola, Shama Lydia, Jan Ossenkoppele, Gert, Vellenga, Edo, van den Berg-de Ruiter, Eva, Schanz, Urs, Verhoef, Gregor, Vandenberghe, Peter, Ferrant, Augustin, Köhne, Claus-Henning, Pfreundschuh, Michael, Horst, Heinz A., Koller, Elisabeth, von Lilienfeld-Toal, Marie, Bentz, Martin, Ganser, Arnold, Schlegelberger, Brigitte, Jotterand, Martine, Krauter, Jürgen, Pabst, Thomas, Theobald, Matthias, Schlenk, Richard F., Delwel, Ruud, Döhner, Konstanze, Löwenberg, Bob, Döhner, Hartmut · 2010 · Journal of Clinical Oncology

Abstract

Purpose: Acute myeloid leukemia (AML) with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) [inv(3)/t(3;3)] is recognized as a distinctive entity in the WHO classification. Risk assignment and clinical and genetic characterization of AML with chromosome 3q abnormalities other than inv(3)/t(3;3) remain largely unresolved. Patients and Methods: Cytogenetics, molecular genetics, therapy response, and outcome analysis were performed in 6,515 newly diagnosed adult AML patients. Patients were treated on Dutch-Belgian Hemato-Oncology Cooperative Group/Swiss Group for Clinical Cancer Research (HOVON/SAKK; n = 3,501) and German-Austrian Acute Myeloid Leukemia Study Group (AMLSG; n = 3,014) protocols. EVI1 and MDS1/EVI1 expression was determined by real-time quantitative polymerase chain reaction. Results: 3q abnormalities were detected in 4.4% of AML patients (288 of 6,515). Four distinct groups were defined: A: inv(3)/t(3;3), 32%; B: balanced t(3q26), 18%; C: balanced t(3q21), 7%; and D: other 3q abnormalities, 43%. Monosomy 7 was the most common additional aberration in groups (A), 66%; (B), 31%; and (D), 37%. N-RAS mutations and dissociate EVI1 versus MDS1/EVI1 overexpression were associated with inv(3)/t(3;3). Patients with inv(3)/t(3;3) and balanced t(3q21) at diagnosis presented with higher WBC and platelet counts. In multivariable analysis, only inv(3)/t(3;3), but not t(3q26) and t(3q21), predicted reduced relapse-free survival (hazard ratio [HR], 1.99; P < .001) and overall survival (HR, 1.4; P = .006). This adverse prognostic impact of inv(3)/t(3;3) was enhanced by additional monosomy 7. Group D 3q aberrant AML also had a poor outcome related to the coexistence of complex and/or monosomal karyotypes and cryptic inv(3)/t(3;3). Conclusion: Various categories of 3q abnormalities in AML can be distinguished according to their clinical, hematologic, and genetic features. AML with inv(3)/t(3;3) represents a distinctive subgroup with unfavorable prognosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2010.29.2771

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 256

Metadata

Authors
Lugthart, S., Gröschel, S., Beverloo, H. B., Kayser, S., Valk, P. J. M., van Zelderen-Bhola, S. L., Jan Ossenkoppele, G., Vellenga, E., van den Berg-de Ruiter, E., Schanz, U., Verhoef, G., Vandenberghe, P., Ferrant, A., Köhne, C.-H., Pfreundschuh, M., Horst, H. A., Koller, E., von Lilienfeld-Toal, M., Bentz, M., Ganser, A., Schlegelberger, B., Jotterand, M., Krauter, J., Pabst, T., Theobald, M., Schlenk, R. F., Delwel, R., Döhner, K., Löwenberg, B., & Döhner, H.
Venue
Journal of Clinical Oncology
Published
2010-08-20
Volume
28
Issue
24
Pages
3890-3898
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2170510628
Cited by
256
References
34
FWCI
9.70
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia. https://app.cochat.ai/papers/10.1200/jco.2010.29.2771
The paper
Lugthart, S., Gröschel, S., Beverloo, H. B., Kayser, S., Valk, P. J. M., van Zelderen-Bhola, S. L., Jan Ossenkoppele, G., Vellenga, E., van den Berg-de Ruiter, E., Schanz, U., Verhoef, G., Vandenberghe, P., Ferrant, A., Köhne, C.-H., Pfreundschuh, M., Horst, H. A., Koller, E., von Lilienfeld-Toal, M., Bentz, M., . . . Döhner, H. (2010). Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.29.2771

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.